v3.20.4
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]      
Net revenues $ 45,804 $ 33,266 $ 32,753
Cost of products sold 15,387 7,439 7,718
Selling, general and administrative 11,299 6,942 7,399
Research and development 6,557 6,407 10,329
Acquired in-process research and development 1,198 385 424
Other operating (income) expense 0 (890) 500
Total operating costs and expenses 34,441 20,283 26,370
Operating earnings 11,363 12,983 6,383
Interest expense, net 2,280 1,509 1,144
Net foreign exchange loss 71 42 24
Other expense, net 5,614 3,006 18
Earnings before income tax expense 3,398 8,426 5,197
Income tax expense (benefit) (1,224) 544 (490)
Net earnings 4,622 7,882 5,687
Net earnings attributable to noncontrolling interest 6 0 0
Net earnings attributable to AbbVie Inc. $ 4,616 $ 7,882 $ 5,687
Per share data      
Basic earnings per share (in dollars per share) $ 2.73 $ 5.30 $ 3.67
Diluted earnings per share (in dollars per share) $ 2.72 $ 5.28 $ 3.66
Weighted-average basic shares outstanding (in shares) 1,667 1,481 1,541
Weighted-average diluted shares outstanding (in shares) 1,673 1,484 1,546